New combo therapy aims to slow advanced breast cancer in patients who've already tried hormone treatment
NCT ID NCT07195227
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 28 times
Summary
This study tests a combination of two drugs, camizestrant and ribociclib, in 150 adults with advanced hormone receptor-positive (HR+) breast cancer. Participants must have had at least 5 years of prior hormone therapy. The goal is to see if the combination can delay cancer growth longer than current treatments. This is a phase 2 trial, meaning it's still being tested for effectiveness and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.